Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Alnylam Acquires Rights To VEGF Patents From Hybridon

Aug. 5, 2004

By Aaron Lorenzo

Elusys Raises $10.2M Via Series D Financing Round

Aug. 4, 2004

By Aaron Lorenzo

Elusys Raises $10.2M Via Series D Financing Round

Aug. 4, 2004

By Aaron Lorenzo

Though Not Approved, La Jolla's Riquent Begins Phase IV Study

Aug. 3, 2004

By Aaron Lorenzo

Though Not Approved, La Jolla's Riquent Begins Phase IV Study

Aug. 3, 2004

By Aaron Lorenzo

CV Therapeutics Gets Second Ranexa SPA For Angina, ACS

Aug. 2, 2004

By Aaron Lorenzo

CV Therapeutics Gets Second Ranexa SPA For Angina, ACS

Aug. 2, 2004

By Aaron Lorenzo

SGX Acquires First Clinical Drug: Troxatyl For Cancer

July 30, 2004

By Aaron Lorenzo

SGX Acquires First Clinical Drug: Troxatyl For Cancer

July 30, 2004

By Aaron Lorenzo

MannKind IPO Prices Within Range; Shares Close Higher

July 29, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...